IL119029A0 - Long-acting drugs and pharamaceutical compositions comprising them - Google Patents

Long-acting drugs and pharamaceutical compositions comprising them

Info

Publication number
IL119029A0
IL119029A0 IL11902996A IL11902996A IL119029A0 IL 119029 A0 IL119029 A0 IL 119029A0 IL 11902996 A IL11902996 A IL 11902996A IL 11902996 A IL11902996 A IL 11902996A IL 119029 A0 IL119029 A0 IL 119029A0
Authority
IL
Israel
Prior art keywords
peptide
hirudin
conjugates
long
acting drugs
Prior art date
Application number
IL11902996A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL11902996A priority Critical patent/IL119029A0/xx
Publication of IL119029A0 publication Critical patent/IL119029A0/xx
Priority to PCT/IL1997/000265 priority patent/WO1998005361A2/en
Priority to CN97197122A priority patent/CN1227501A/zh
Priority to CA002261835A priority patent/CA2261835C/en
Priority to AU37060/97A priority patent/AU725468B2/en
Priority to DK97933828T priority patent/DK1019089T3/da
Priority to DE69734607T priority patent/DE69734607T2/de
Priority to ES97933828T priority patent/ES2252787T3/es
Priority to US09/242,026 priority patent/US6504005B1/en
Priority to KR1019997000941A priority patent/KR20000029806A/ko
Priority to AT97933828T priority patent/ATE308998T1/de
Priority to NZ333845A priority patent/NZ333845A/xx
Priority to IL12827497A priority patent/IL128274A0/xx
Priority to BR9711045A priority patent/BR9711045A/pt
Priority to HU0000809A priority patent/HUP0000809A2/hu
Priority to CZ99369A priority patent/CZ36999A3/cs
Priority to EP97933828A priority patent/EP1019089B1/en
Priority to JP50777098A priority patent/JP4416184B2/ja
Priority to IL128274A priority patent/IL128274A/en
Priority to NO990518A priority patent/NO990518L/no
Priority to US10/408,262 priority patent/US20040092443A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL11902996A 1996-08-06 1996-08-07 Long-acting drugs and pharamaceutical compositions comprising them IL119029A0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
IL11902996A IL119029A0 (en) 1996-08-07 1996-08-07 Long-acting drugs and pharamaceutical compositions comprising them
JP50777098A JP4416184B2 (ja) 1996-08-07 1997-08-05 長期作用型薬物およびこれらを含む薬剤組成物
US09/242,026 US6504005B1 (en) 1996-08-07 1997-08-05 Long-acting drugs and pharmaceutical compositions comprising them
AT97933828T ATE308998T1 (de) 1996-08-07 1997-08-05 Langwirkende arzneistoffe und diese enthaltende arzneimittel
CA002261835A CA2261835C (en) 1996-08-07 1997-08-05 Long-acting drugs and pharmaceutical compositions comprising them
AU37060/97A AU725468B2 (en) 1996-08-07 1997-08-05 Long-acting drugs and pharmaceutical compositions comprising them
DK97933828T DK1019089T3 (da) 1996-08-07 1997-08-05 Langtidsvirkende lægemidler og farmaceutiske præparater der omfatter disse
DE69734607T DE69734607T2 (de) 1996-08-07 1997-08-05 Langwirkende arzneistoffe und diese enthaltende arzneimittel
ES97933828T ES2252787T3 (es) 1996-08-07 1997-08-05 Principios activos de efecto prolongado y composciones farmaceuticas que los incluyen.
PCT/IL1997/000265 WO1998005361A2 (en) 1996-08-07 1997-08-05 Long-acting drugs and pharmaceutical compositions comprising them
KR1019997000941A KR20000029806A (ko) 1996-08-07 1997-08-05 장기간-작용의약및이를포함한약제학적조성물
CN97197122A CN1227501A (zh) 1996-08-07 1997-08-05 长效药物及含有该长效药物的药物组合物
NZ333845A NZ333845A (en) 1996-08-07 1997-08-05 Long-acting Fmoc-substituted and Fm-substituted pro-drugs
IL12827497A IL128274A0 (en) 1996-08-07 1997-08-05 Long-acting drugs and pharmaceutical compositions comprising them
BR9711045A BR9711045A (pt) 1996-08-07 1997-08-05 Drogas de atua-Æo prolongada e composi-{es farmac-uticas compreendendo as mesmas
HU0000809A HUP0000809A2 (hu) 1996-08-07 1997-08-05 Hosszan ható hatóanyagok és azokat tartalmazó gyógyszerkészítmények
CZ99369A CZ36999A3 (cs) 1996-08-07 1997-08-05 Dlouho působící farmaceutika a farmaceutické sloučeniny, které obsahují tyto látky
EP97933828A EP1019089B1 (en) 1996-08-07 1997-08-05 Long-acting drugs and pharmaceutical compositions comprising them
IL128274A IL128274A (en) 1996-08-07 1999-01-28 Long-acting drugs and pharmaceutical compositions comprising them
NO990518A NO990518L (no) 1996-08-07 1999-02-04 Langtidsvirkende medikamenter og farmas°ytiske sammensetninger som omfatter disse
US10/408,262 US20040092443A1 (en) 1996-08-06 2003-04-08 Long-acting exendins and exendin agonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11902996A IL119029A0 (en) 1996-08-07 1996-08-07 Long-acting drugs and pharamaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
IL119029A0 true IL119029A0 (en) 1996-11-14

Family

ID=11069166

Family Applications (3)

Application Number Title Priority Date Filing Date
IL11902996A IL119029A0 (en) 1996-08-06 1996-08-07 Long-acting drugs and pharamaceutical compositions comprising them
IL12827497A IL128274A0 (en) 1996-08-07 1997-08-05 Long-acting drugs and pharmaceutical compositions comprising them
IL128274A IL128274A (en) 1996-08-07 1999-01-28 Long-acting drugs and pharmaceutical compositions comprising them

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL12827497A IL128274A0 (en) 1996-08-07 1997-08-05 Long-acting drugs and pharmaceutical compositions comprising them
IL128274A IL128274A (en) 1996-08-07 1999-01-28 Long-acting drugs and pharmaceutical compositions comprising them

Country Status (18)

Country Link
US (1) US6504005B1 (enExample)
EP (1) EP1019089B1 (enExample)
JP (1) JP4416184B2 (enExample)
KR (1) KR20000029806A (enExample)
CN (1) CN1227501A (enExample)
AT (1) ATE308998T1 (enExample)
AU (1) AU725468B2 (enExample)
BR (1) BR9711045A (enExample)
CA (1) CA2261835C (enExample)
CZ (1) CZ36999A3 (enExample)
DE (1) DE69734607T2 (enExample)
DK (1) DK1019089T3 (enExample)
ES (1) ES2252787T3 (enExample)
HU (1) HUP0000809A2 (enExample)
IL (3) IL119029A0 (enExample)
NO (1) NO990518L (enExample)
NZ (1) NZ333845A (enExample)
WO (1) WO1998005361A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139400A0 (en) * 2000-11-01 2001-11-25 Yeda Res & Dev Long-acting cytokine derivatives and pharmaceutical compositions comprising them
EP2186824A3 (en) * 2000-12-13 2010-09-22 Eli Lilly & Company Chronic treatment regimen using glucagon-like insulinotropic peptides
BRPI0213425B8 (pt) 2001-10-19 2021-05-25 Idexx Lab Inc composições injetáveis para a liberação controlada de composto farmacologicamente ativo, usos do referido composto e método para suas preparações
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
JP4033382B2 (ja) * 2002-04-08 2008-01-16 久光製薬株式会社 インスリン投与装置
DE602004030212D1 (de) * 2003-01-16 2011-01-05 Caprotec Bioanalytics Gmbh Verfahren zur identifizierung von auf arzneimittel nicht-zielgerichteten proteinen
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
ATE347358T1 (de) * 2003-04-17 2006-12-15 Jallal Messadek Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
EP2107069B1 (en) 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
US7282487B2 (en) * 2004-10-28 2007-10-16 Idexx Laboratories Method for treating bacterial infections in horses or pigs with tilmicosin
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
CN101180073A (zh) * 2005-04-27 2008-05-14 贾拉尔·梅萨德克 胰岛素组合
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
WO2009158668A1 (en) 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010048184A2 (en) * 2008-10-21 2010-04-29 Baxter International Inc. Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation)
KR20110085985A (ko) * 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
CN102413843A (zh) 2009-03-05 2012-04-11 阿森迪斯药物股份有限公司 干扰素α载体前药
WO2011013128A2 (en) 2009-07-31 2011-02-03 Yeda Research And Development Co. Ltd. Vectors for delivery of neurotherapeutics to the central nervous system
ES2584381T3 (es) * 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
EP2490378B1 (en) 2011-02-18 2014-07-09 NTT DoCoMo, Inc. Apparatus and method for determining a control unit using feasibility requests and feasibility responses
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
EP2714070B1 (en) 2011-06-02 2024-03-20 OPKO Biologics Ltd. Long-acting glp-1/glucagon receptor agonists
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
PE20150181A1 (es) 2012-06-04 2015-02-28 Opko Biolog Ltd Variantes de oxm pegilada
EP2869830B1 (en) 2012-07-09 2016-10-12 Novo Nordisk A/S Novel use of insulin derivatives
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
US20200254065A1 (en) 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CN114630818A (zh) 2019-09-30 2022-06-14 北京轩义医药科技有限公司 蛋白-大分子偶联物及其使用方法
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
CN117551008B (zh) * 2023-11-10 2025-10-17 沈阳药科大学 一种去铁胺偶联物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU906341D0 (en) 1986-10-13 1991-04-29 Sandoz Ag Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US6313094B1 (en) * 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
JPH0687887A (ja) * 1992-08-19 1994-03-29 Upjohn Co:The ペプチドのエナミン誘導体およびそれをプロドラッグとして含有するペプチド製剤
US5631222A (en) 1993-06-25 1997-05-20 Kyowa Hakko Kogyo Co., Ltd. Endothelin-antagonizing peptide
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
JPH10511340A (ja) 1995-02-09 1998-11-04 ブリガム アンド ウィメンズ ホスピタル ゲル生成ポリペプチド誘導体
AU5377296A (en) * 1995-03-30 1996-10-16 Southpac Trust International, Inc. Self-erecting container which is collapsible to be substanti ally flat
US5688992A (en) * 1995-03-31 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof
US5846934A (en) * 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
US6057297A (en) * 1996-08-06 2000-05-02 Polifarma S.P.A. Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof

Also Published As

Publication number Publication date
ES2252787T3 (es) 2006-05-16
WO1998005361A2 (en) 1998-02-12
HUP0000809A2 (hu) 2000-11-28
EP1019089A2 (en) 2000-07-19
NZ333845A (en) 2000-09-29
AU3706097A (en) 1998-02-25
IL128274A0 (en) 1999-11-30
DK1019089T3 (da) 2006-03-13
NO990518L (no) 1999-04-06
NO990518D0 (no) 1999-02-04
JP4416184B2 (ja) 2010-02-17
US6504005B1 (en) 2003-01-07
AU725468B2 (en) 2000-10-12
BR9711045A (pt) 1999-08-17
CA2261835C (en) 2008-07-29
WO1998005361A3 (en) 1998-06-18
DE69734607D1 (de) 2005-12-15
DE69734607T2 (de) 2006-08-03
IL128274A (en) 2006-08-01
CN1227501A (zh) 1999-09-01
KR20000029806A (ko) 2000-05-25
JP2000515542A (ja) 2000-11-21
CZ36999A3 (cs) 1999-07-14
ATE308998T1 (de) 2005-11-15
EP1019089B1 (en) 2005-11-09
CA2261835A1 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
IL128274A0 (en) Long-acting drugs and pharmaceutical compositions comprising them
IL135148A0 (en) A polysaccharide conjugate and pharmaceutical compositions containing the same
SG46223A1 (en) Amplification of the vb12 uptake system using polymers
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
IL113812A0 (en) Copolymer-1, pharmaceutical compositions containing it and its use
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
EP1705190A3 (en) Peptide derivatives
MY102878A (en) Starburst conjugates
MX9700222A (es) Derivados de camptotecina.
NL194828B (nl) Somatostatinepeptiden, alsmede dergelijke somatostatinepeptiden bevattende farmaceutische preparaten.
PH31059A (en) Pharmaceutical compositions comprising cyclosporins.
SI0984982T1 (en) Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them
WO2000023094A3 (en) Methods of inhibiting platelet activation and recruitment
EP1003526A4 (en) COVALENT-TIED N, O-CARBOXYMETHYLCHITOSAN AND ITS USE
IL111533A0 (en) Quinoxalinedione derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
WO2000015244A3 (de) Pharmazeutische zubereitung enthaltend ein cyclo-peptide und ein chemotherapeutikum oder einen angiogeneseinhibitor
CA2114313A1 (en) Bpc peptides, their preparation and use
IL96326A0 (en) Polymyxin conjugates,their preparation and pharmaceutical compositions containing them
WO1998019697A3 (en) Novel pharmaceutical compositions
AU7683296A (en) Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them
WO1996041868A3 (de) Prothrombin-derivate
EP1006126A3 (en) Osteogenic peptides
EP0367489A3 (en) Thromboresistant materials and methods for making same
DZ1576A1 (fr) Compostions therapeutiques à base de dérives de 1,2-dithiole-3-thione.
EP0372503A3 (en) Anticoagulant peptides